Synopsis
Synopsis
0
KDMF
0
VMF
0
FDF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Chloramiphene
2. Citrate, Clomiphene
3. Clomid
4. Clomide
5. Clomifen
6. Clomifene
7. Clomiphene
8. Clomiphene Citrate
9. Clomiphene Hydrochloride
10. Clostilbegit
11. Dyneric
12. Gravosan
13. Hydrochloride, Clomiphene
14. Klostilbegit
15. Serophene
1. Clomiphene Citrate
2. 50-41-9
3. Zuclomiphene Citrate
4. Cis-clomiphene Citrate
5. Clomid
6. Zuclomid
7. Clomiphene A Citrate
8. 7619-53-6
9. Clomiphene Citrate Salt
10. Milophene
11. Serophene
12. (z)-clomiphene Citrate
13. Chloramiphene
14. Omifin
15. Rmi 16289
16. Clomivid
17. Clomphid
18. Dyneric
19. Genozym
20. Ikaclomin
21. Clomifene Citrate (serophene)
22. Zuclomiphene (citrate)
23. Uy5x264qzv
24. Mrl 41
25. Nsc-151466
26. 2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-n,n-diethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate
27. Nsc 35770
28. Rmi 16312
29. 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic Acid
30. Ethanamine, 2-(4-((1z)-2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
31. Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-n,n-diethyl-,2-hydroxy-1,2,3-propanetricarboxylate (1:1)
32. Mer-41
33. Mrl-41
34. Unii-uy5x264qzv
35. Nsc 151466
36. Nsc-35770
37. Cas-50-41-9
38. Clomiphene Citrate, Cis-
39. Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, Citrate (1:1), (z)-
40. Mls001332629
41. Mls002207099
42. Schembl223472
43. Spectrum1500196
44. Sgcut00109
45. Chembl1213137
46. Hms501h04
47. Hy-b1617a
48. Hms1920o19
49. Hms2091g06
50. Hms2232d12
51. Pharmakon1600-01500196
52. Amy33425
53. Bcp03057
54. To_000032
55. Ccg-39553
56. Nsc151466
57. Nsc756698
58. S2561
59. Akos005111131
60. Bcp9000541
61. Ds-6814
62. Fd12066
63. Nsc-756698
64. Ncgc00017008-01
65. Ncgc00017008-02
66. Ncgc00017008-03
67. Ncgc00094626-01
68. Ncgc00094626-02
69. Ncgc00164385-01
70. Ac-19685
71. Ac-32011
72. Ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethyl-, (z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
73. Bcp0726000214
74. Cs-0111663
75. Sw196898-3
76. C08161
77. Triethylamine,2-diphenylvinyl)phenoxy]-, Citrate
78. Sr-05000001591
79. Sr-05000001591-1
80. Q27291328
81. Triethylamine,2-diphenylvinyl)phenoxy]-, Citrate (1:1)
82. Triethylamine,2-diphenylvinyl)phenoxy]-, Citrate (1:1), (z)-
83. (2)2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]triethylamine Citrate (1:1)
84. 2-(4-[2-chloro-1,2-diphenylethenyl]phenoxy)-n,n-diethylethanamine Citrate Salt
85. {2-[4-(2-chloro-1,2-diphenylvinyl)phenoxy]ethyl}diethylamine 2-hydroxypropane-1,2,3-tricarboxylic Acid Salt
86. 2-({4-[(z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-n,n-diethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt)
87. Ethanamine,2-diphenylethenyl)phenoxy]-n,n-diethyl-, (z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
88. Ethanamine,2-diphenylethenyl)phenoxy]-n,n-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Molecular Weight | 598.1 g/mol |
---|---|
Molecular Formula | C32H36ClNO8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 14 |
Exact Mass | 597.2129448 g/mol |
Monoisotopic Mass | 597.2129448 g/mol |
Topological Polar Surface Area | 145 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 708 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Clomid |
PubMed Health | Clomiphene (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Female Reproductive Agent |
Drug Label | Clomiphene citrate tablets, USP is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2chloro-1,2-diphenylvinyl)phenoxy] triethylamine citrate (1:1). It has the molecular formula of C26H28CINO C6H8O7 and a mo... |
Active Ingredient | Clomiphene citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Sanofi Aventis Us |
2 of 6 | |
---|---|
Drug Name | Clomiphene citrate |
PubMed Health | Clomiphene (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Female Reproductive Agent |
Drug Label | ClomiPHENE citrate is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2-chloro-1,2-diphenylvinyl) phenoxy] triethylamine citrate (1:1). It has a molecular formula of C26H28CINO C6H8O7 and a molecular weig... |
Active Ingredient | Clomiphene citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Par Pharm |
3 of 6 | |
---|---|
Drug Name | Serophene |
Active Ingredient | Clomiphene citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Emd Serono |
4 of 6 | |
---|---|
Drug Name | Clomid |
PubMed Health | Clomiphene (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Female Reproductive Agent |
Drug Label | Clomiphene citrate tablets, USP is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2chloro-1,2-diphenylvinyl)phenoxy] triethylamine citrate (1:1). It has the molecular formula of C26H28CINO C6H8O7 and a mo... |
Active Ingredient | Clomiphene citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Sanofi Aventis Us |
5 of 6 | |
---|---|
Drug Name | Clomiphene citrate |
PubMed Health | Clomiphene (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Female Reproductive Agent |
Drug Label | ClomiPHENE citrate is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2-chloro-1,2-diphenylvinyl) phenoxy] triethylamine citrate (1:1). It has a molecular formula of C26H28CINO C6H8O7 and a molecular weig... |
Active Ingredient | Clomiphene citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Par Pharm |
6 of 6 | |
---|---|
Drug Name | Serophene |
Active Ingredient | Clomiphene citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Emd Serono |
Fertility Agents, Female
Compounds which increase the capacity to conceive in females. (See all compounds classified as Fertility Agents, Female.)
Estrogen Antagonists
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)
Selective Estrogen Receptor Modulators
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
33
PharmaCompass offers a list of Clomiphene Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Clomiphene Citrate manufacturer or Clomiphene Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Clomiphene Citrate manufacturer or Clomiphene Citrate supplier.
PharmaCompass also assists you with knowing the Clomiphene Citrate API Price utilized in the formulation of products. Clomiphene Citrate API Price is not always fixed or binding as the Clomiphene Citrate Price is obtained through a variety of data sources. The Clomiphene Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CLOMIPHENE-CITRATE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CLOMIPHENE-CITRATE, including repackagers and relabelers. The FDA regulates CLOMIPHENE-CITRATE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CLOMIPHENE-CITRATE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CLOMIPHENE-CITRATE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CLOMIPHENE-CITRATE supplier is an individual or a company that provides CLOMIPHENE-CITRATE active pharmaceutical ingredient (API) or CLOMIPHENE-CITRATE finished formulations upon request. The CLOMIPHENE-CITRATE suppliers may include CLOMIPHENE-CITRATE API manufacturers, exporters, distributors and traders.
click here to find a list of CLOMIPHENE-CITRATE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CLOMIPHENE-CITRATE DMF (Drug Master File) is a document detailing the whole manufacturing process of CLOMIPHENE-CITRATE active pharmaceutical ingredient (API) in detail. Different forms of CLOMIPHENE-CITRATE DMFs exist exist since differing nations have different regulations, such as CLOMIPHENE-CITRATE USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CLOMIPHENE-CITRATE DMF submitted to regulatory agencies in the US is known as a USDMF. CLOMIPHENE-CITRATE USDMF includes data on CLOMIPHENE-CITRATE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CLOMIPHENE-CITRATE USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CLOMIPHENE-CITRATE suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CLOMIPHENE-CITRATE Drug Master File in Japan (CLOMIPHENE-CITRATE JDMF) empowers CLOMIPHENE-CITRATE API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CLOMIPHENE-CITRATE JDMF during the approval evaluation for pharmaceutical products. At the time of CLOMIPHENE-CITRATE JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CLOMIPHENE-CITRATE suppliers with JDMF on PharmaCompass.
A CLOMIPHENE-CITRATE CEP of the European Pharmacopoeia monograph is often referred to as a CLOMIPHENE-CITRATE Certificate of Suitability (COS). The purpose of a CLOMIPHENE-CITRATE CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CLOMIPHENE-CITRATE EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CLOMIPHENE-CITRATE to their clients by showing that a CLOMIPHENE-CITRATE CEP has been issued for it. The manufacturer submits a CLOMIPHENE-CITRATE CEP (COS) as part of the market authorization procedure, and it takes on the role of a CLOMIPHENE-CITRATE CEP holder for the record. Additionally, the data presented in the CLOMIPHENE-CITRATE CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CLOMIPHENE-CITRATE DMF.
A CLOMIPHENE-CITRATE CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CLOMIPHENE-CITRATE CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CLOMIPHENE-CITRATE suppliers with CEP (COS) on PharmaCompass.
A CLOMIPHENE-CITRATE written confirmation (CLOMIPHENE-CITRATE WC) is an official document issued by a regulatory agency to a CLOMIPHENE-CITRATE manufacturer, verifying that the manufacturing facility of a CLOMIPHENE-CITRATE active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CLOMIPHENE-CITRATE APIs or CLOMIPHENE-CITRATE finished pharmaceutical products to another nation, regulatory agencies frequently require a CLOMIPHENE-CITRATE WC (written confirmation) as part of the regulatory process.
click here to find a list of CLOMIPHENE-CITRATE suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CLOMIPHENE-CITRATE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CLOMIPHENE-CITRATE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CLOMIPHENE-CITRATE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CLOMIPHENE-CITRATE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CLOMIPHENE-CITRATE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CLOMIPHENE-CITRATE suppliers with NDC on PharmaCompass.
CLOMIPHENE-CITRATE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CLOMIPHENE-CITRATE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CLOMIPHENE-CITRATE GMP manufacturer or CLOMIPHENE-CITRATE GMP API supplier for your needs.
A CLOMIPHENE-CITRATE CoA (Certificate of Analysis) is a formal document that attests to CLOMIPHENE-CITRATE's compliance with CLOMIPHENE-CITRATE specifications and serves as a tool for batch-level quality control.
CLOMIPHENE-CITRATE CoA mostly includes findings from lab analyses of a specific batch. For each CLOMIPHENE-CITRATE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CLOMIPHENE-CITRATE may be tested according to a variety of international standards, such as European Pharmacopoeia (CLOMIPHENE-CITRATE EP), CLOMIPHENE-CITRATE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CLOMIPHENE-CITRATE USP).